News

Nihon Keizai Shimbun March 13, 2017 Fujifilm Group runs clinical trial of medical treatment targeting bone marrow transplant side effects using donated iPS cells in the U.K. Cynata Therapeutics, Ltd., an Australia-based bioventure...

Read More

Good news for more than 2 million Australians who suffer from asthma, with scientists a step closer to a cure after ground-breaking research at one of our universities. Karen O'Sullivan...

Read More

CPS Capital CEO, Jason Peterson advised current and potential investors that as a major shareholder of Cynata Therapeutics Ltd (“CYP”), he has recently been meeting management, organising a marketing strategy...

Read More

Sistemic Ltd. and Cynata Therapeutics Limited (ASX:CYP) announced today that they have entered into an agreement which will see Sistemic use its novel SistemQC™ miRNA technology platforms, together with its...

Read More

Cynata Therapeutics Limited CYP-AU: Price: A$0.30; Market Cap (MM): A$22 Rating: Buy; Price Target: A$1.00 Raghuram Selvaraju, Ph.D., Senior Biotechnology Analyst MHRA Favorable Advice Received; Proceeding to Clinical Testing Click here for complete report and disclosures Regulatory...

Read More